NEW YORK (GenomeWeb News) – Fluidigm said today it has signed up AME Bioscience to distribute its integrated fluidic circuits in the Nordic region.
Under the exclusive agreement, AME Bioscience will distribute Fluidigm’s BioMark systems to research customers in Norway, Sweden, Iceland, Finland, and Denmark.
The BioMark system, which has not been cleared or approved by the US Food and Drug Administration for use as a diagnostic, is used in real-time PCR, genotyping, cancer detection, and absolute quantification for research purposes.
Financial terms of the agreement were not released.